Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL

Prof David Teachey - The University of Pennsylvania, Rutledge, USA

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )

ecancer special issue on immunotherapy

Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy

ecancer special issue on immunotherapy ( Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy )

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA

PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells

Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells ( Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom )

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Updates in geriatric oncology from SIOG 2020

Dr Siri Rostoft - Oslo University Hospital, Oslo, Norway

Updates in geriatric oncology from SIOG 2020 ( Dr Siri Rostoft - Oslo University Hospital, Oslo, Norway )

Clinical genomic testing in prostate cancer

Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA

Clinical genomic testing in prostate cancer ( Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA )

More from ecancer